ASH 2023: Real-World Treatment Outcomes for Multiple Myeloma Worse Than Trial Outcomes
Real-world patients experience 44 percent worse progression-free survival and 75 percent worse overall survival versus trial participants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.